Intelligence / Healthtech / New Clinical Trials / Keymed Biosciences Co.Ltd
Clinicaltrial registered23 Oct 2026
Keymed Biosciences Co.Ltd
23 Oct 2026: Trial registered · Study of CM529D1 in Participants With Advanced Solid Tumors. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 23 Oct 2026
- Title
- Study of CM529D1 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Phase
- Phase 1, Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07893171
- Location
- China
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Keymed Biosciences Co.Ltd
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Keymed Biosciences Co.Ltd in our registers.
2 NovKeymed Biosciences Co.Ltdtrial registered · HealthtechClinical28 OctKeymed Biosciences Co.Ltdtrial registered · HealthtechClinical
More from China
New Clinical Trials
18 NovBeijing Baheal Wisart Medical Research Co., Ltdtrial registered · Safety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Dose of YY524051 Tablets in Healthy Adults.Clinical18 NovBeijing Xunsheng Biomedical Research Co., Ltd.trial registered · Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV16/18 InfectionClinical18 NovCASI pharmaceuticals, Inc.trial registered · A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune ThrombocytopeniaClinical18 NovEli Lilly and Companytrial registered · A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy ParticipantsClinical18 NovFujian Akeylink Biotechnology Co., Ltd.trial registered · A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal Liver FunctionClinical18 NovGan & Lee Pharmaceuticals.trial registered · A Pharmacokinetics Study of GZR33 Injection at Different Injection SitesClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.